Abstracts tagged "interstitial lung disease"

Abstract Number: 0490 • ACR Convergence 2020
Fine Specificity Anti-Citrullinated Protein Antibodies as Biomarkers for Prediction of Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease
Vanessa Kronzer¹, Weixing Huang², Paul Dellaripa³, Sicong Huang⁴, Vivi Feathers², Bing Lu⁵, Christine Iannaccone⁴, Ritu Gill⁶, Hiroto Hatabu⁷, Mizuki Nishino⁷, Cynthia Crowson⁸, John Davis¹, William Robinson⁹, Tripta Rughwani⁹, Jeremy Sokolove¹⁰, Michael Weinblatt⁴, Nancy Shadick¹¹, Tracy J. Doyle¹² and Jeffrey Sparks¹¹, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁶Beth Israel Deaconess Medical Center, Boston, MA, ⁷Department of Radiology; Brigham and Women’s Hospital, Boston, ⁸Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ⁹Stanford University, Palo Alto, CA, ¹⁰Stanford University, Mountain View, CA, ¹¹Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹²Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: Seropositivity for anti-citrullinated protein antibodies (ACPA) has been shown to increase risk for RA-associated interstitial lung disease (RA-ILD). However, RA-related autoantibodies used in clinical…
Abstract Number: 1056 • ACR Convergence 2020
Descriptive Data Analysis of Patients with Anti Jo1 Syndrome (AJS) and Lung Involvement
Mohamed Alalwani¹, Bassam Alhaddad², Basem Zraik³, Christopher O'Rourke³, Ruchi Yadav³, Ali Askari¹, Charles Malemud¹ and Soumya Chatterjee⁴, ¹Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, OH, ²MetroHealth Medical Center, Westlake, OH, ³Cleveland Clinic, Cleveland, OH, ⁴Cleveland Clinic, Richmond Heights, OH
Background/Purpose: To evaluate the patterns, severity and, prognostic parameters of interstitial lung disease (ILD) in Anti Jo1 Syndrome (AJS).Methods: We identified 51 anti-Jo-1 patients with…
Abstract Number: 1200 • ACR Convergence 2020
Serum Anti-PAD4 and Anti-PAD3/4XR Antibodies in Rheumatoid Arthritis Associated-Interstitial Lung Disease Are Associated with Better Lung Function
Tim Wilson¹, Joshua Solomon², Jeffrey Swigris², Erika Darrah³ and M Kristen Demoruelle¹, ¹University of Colorado, Denver, CO, ²National Jewish Health, Denver, CO, ³Division of Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Rheumatoid arthritis (RA) associated-interstitial lung disease (ILD) affects approximately 10% of RA patients. It is a leading cause of morbidity and mortality, which is…
Abstract Number: 0491 • ACR Convergence 2020
Relationship Between Rheumatoid Arthritis and Pulmonary Function in the UK Biobank
Lauren C. Prisco¹, Matthew Moll¹, Jiaqi Wang², Weixing Huang³, Lily Martin¹, Vanessa Kronzer⁴, Sicong Huang², Edwin Silverman², Tracy J. Doyle⁵, Michael Cho⁵ and Jeffrey Sparks⁶, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁴Mayo Clinic, Rochester, MN, ⁵Brigham and Women's Hospital, West Roxbury, MA, ⁶Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Established pulmonary manifestations of RA include restrictive processes such as interstitial lung disease and obstructive processes such as bronchiectasis, but clinically detected forms of…
Abstract Number: 1067 • ACR Convergence 2020
Anti-Viral Proinflammatory Phenotype in Circulating Monocytes from Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Associated Interstitial Lung Disease
Takahisa Gono¹, Yuka Okazaki¹ and Masataka Kuwana², ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody is associated with interstitial lung disease (ILD), which often represents rapidly progressive course and fatal outcomes. Circulating levels…
Abstract Number: 1244 • ACR Convergence 2020
Clinical Characteristics and Outcomes in Patients with Primary Sjögren’s Syndrome-Associated Interstitial Lung Disease
Joanna Marco¹, Gregory Gardner¹ and Nishant Gupta², ¹University of Washington, Seattle, WA, ²University of Cincinnati, Cincinnati
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a chronic autoimmune exocrinopathy that features interstitial lung disease (ILD) in up to 16% of patients. The clinical characteristics…
Abstract Number: 737 • 2019 ACR/ARP Annual Meeting
The MUC5B Promoter Variant Does Not Predict Outcomes in Systemic Sclerosis-related Interstitial Lung Disease
Elizabeth Volkmann¹, Donald Tashkin ², Michael Roth ³, Ning Li ², Grace Kim ², Jonathan Goldin ², Maureen Mayes ⁴, Julio Charles ⁵, Philip Clements ², Daniel Furst ⁶, Dinesh Khanna ⁷, Robert Elashoff ² and Shervin Assassi ⁴, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁵University of Texas, Houston, Houston, ⁶University of California, Los Angeles, CA, ⁷Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Interstitial lung disease (ILD) affects the majority of patients with systemic sclerosis (SSc). The disease course of ILD varies among SSc patients and no…
Abstract Number: 1656 • 2019 ACR/ARP Annual Meeting
Health-Related Quality of Life in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Impact of Lung Function on Patient-Reported Outcomes in a Randomized Phase III Trial
Michael Kreuter ¹, Anna Maria Hoffmann-Vold ², Marco Matucci-Cerinic ³, Lesley Saketkoo ⁴, Kristin Highland⁵, Hilary Wilson ⁶, Margarida Alves ⁷, Nils Schoof ⁶ and Toby Maher ⁸, ¹Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Germany, Germany, Germany, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ³University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, ⁴New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans; Tulane University School of Medicine, University Medical Center – Comprehensive Pulmonary Hypertension Center, USA, New Orleans, ⁵Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom
Background/Purpose: SSc-ILD is a major cause of morbidity and mortality in patients with systemic sclerosis. A subset of patients with SSc-ILD show a decline in…
Abstract Number: 2346 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Abnormalities in Rheumatoid Arthritis Patients: Identifying Associated Risk Factors
Karina Bonfiglioli¹, Márcio Sawamura ², Renato Nakagawa ³, Fábio Arimura ³, Diana Rangel ³, Cleonice Bueno ⁴, Ana Cristina de Medeiros Ribeiro ¹, Carlos Carvalho ³, Eloisa Bonfa ⁵, Ronaldo Kairalla ³ and Leticia Kawano-Dourado ⁶, ¹Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ²Division of Radiology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Br, Sao Paulo, Sao Paulo, Brazil, ³Pulmonary Division, Heart Institute (InCor)- Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁶University of Sao Paulo, Sao Paulo, Brazil
Background/Purpose: A wide spectrum of interstitial lung abnormalities (ILA) occurs in patients with rheumatoid arthritis (RA). This study characterized ILA in large single-center cohort, including…
Abstract Number: 740 • 2019 ACR/ARP Annual Meeting
Rituximab Rescue Therapy in Patients with Systemic Sclerosis or Other Connective Tissue Diseases and Refractory Interstitial Lung Disease
Magdalena Benad ¹, Dirk Koschel ¹, Kristine Herrmann ¹, Kristin Wiefel ¹, Alexander Kleymann ¹ and Martin Aringer², ¹University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany
Background/Purpose: Interstitial lung disease (ILD) is a common and life-threatening organ manifestation of patients with various connective tissue diseases (CTDs), and with systemic sclerosis and…
Abstract Number: 1830 • 2019 ACR/ARP Annual Meeting
Short- and Long-term Morbidity and Mortality Outcomes of African American Patients with Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth Volkmann¹, Virginia Steen ², Ning Li ³, Michael Roth ⁴, Philip Clements ³, Dinesh Khanna ⁵, Daniel Furst ⁶, Shervin Assassi ⁷, Grace Kim ³, Jonathan Goldin ³, Robert Elashoff ³ and Donald Tashkin ³, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ²Georgetown University, Washington, D.C., USA, Georgetown, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ⁴University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁶University of California, Los Angeles, CA, ⁷Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX
Background/Purpose: Observational studies have demonstrated that African American (AA) patients with systemic sclerosis (SSc) have a more unfavorable prognosis compared with non-AA. However, no studies…
Abstract Number: 2360 • 2019 ACR/ARP Annual Meeting
Safety of Biological DMARD in Patients with Interstitial Lung Disease from a Chilean Cohort of Patients with Rheumatoid Arthritis
Silvana Saavedra¹, Karen Vergara ², Claudia Hernandez ², Pedro Zamorano ², Annelise Goecke ², Luis Toro ² and FELIPE REYES ¹, ¹HOSPITAL CLINICO UNIVERSIDAD DE CHILE, Santiago, Chile, ²HOSPITAL CLINICO UNIVERSIDAD DE CHILE, Santiago, Region Metropolitana, Chile
Background/Purpose: Interstitial lung disease (ILD) is a common pulmonary manifestation of rheumatoid arthritis (RA) that may be related to the inflammatory process itself, to infectious…
Abstract Number: 796 • 2019 ACR/ARP Annual Meeting
Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests: Results from the Juvenile Scleroderma Inception Cohort
Ivan Foeldvari¹, Bernd Hinrichs ², Kathryn Torok ³, Maria José Santos ⁴, Ozgur Kasapcopur ⁵, Amra Adrovic ⁶, Valda Stanevicha ⁷, Flavio Sztajnbok ⁸, Maria Teresa Terreri ⁹, Ekaterina Alexeeva ¹⁰, Jordi Antón ¹¹, Maria Katsicas ¹², Vanessa Smith ¹³, Tadej Avcin ¹⁴, Rolando Cimaz ¹⁵, Mikhail Kostik ¹⁶, Thomas Lehman ¹⁷, Walter Sifuentes-Giraldo ¹⁸, Simone Appenzeller ¹⁹, Mahesh Janarthanan ²⁰, Monika Moll ²¹, Dana Nemcova ²², Dieneke Schonenberg ²³, Christina Battagliotti ²⁴, Lillemor Berntson ²⁵, Blanca Bica ²⁶, Juergen Brunner ²⁷, Patricia Costa Reis ²⁸, Despina Eleftheriou ²⁹, Liora Harel ³⁰, Gerd Horneff ³¹, Tilmann Kallinich ³², Dragana Lazarevic ³³, Kirsten Minden ³⁴, Susan Nielsen ³⁵, Farzana Nuruzzaman ³⁶, Anjali Patwardhan ³⁷, Yosef Uziel ³⁸ and Nicola Helmus ¹, ¹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany, ²Asklepios Klinik Nord - Heidberg, Hamburg, Germany, ³UPMC Children's Hospital of Pittsburgh, Pittsburgh, ⁴Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ⁵Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey, ⁶Cerrahpaşa Tıp Fakültesi, Istanbul, Turkey, ⁷Riga Stradins University, Riga, Latvia, ⁸Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁹Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, ¹⁰National Medical Research Center of Children`s Health, Moscow, Russia, ¹¹Hospital Sant Joan de Déu, Barcelona, Spain, ¹²Hospital de Pediatria, Buenos Aires, Argentina, ¹³Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium; Dept. of Internal Medicine, Ghent University, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium, Gent, Belgium, ¹⁴Ljubljana University Medical Centre, Ljubljana, Slovenia, ¹⁵University Hospital Meyer, Florence, Italy, ¹⁶Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, ¹⁷Hospital for Special Surgery, New York, ¹⁸Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁹UNICAMP Universidade Estadual de Campinas, Sao Paulo, Brazil, ²⁰Sri Ramachandra University, Chennai, India, ²¹University of Tuebingen, Tuebingen, Germany, ²²General University Hospital, Prague, Czech Republic, ²³Amsterdam UMC, Amsterdam, Netherlands, ²⁴Children's Hospital Dr. Orlando Alassia, Santa Fee, Argentina, ²⁵Uppsala University Hospital, Uppsala, Sweden, ²⁶Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ), Rio de Janeiro, Brazil, ²⁷Tirol Kliniken, Innsbruck, Austria, ²⁸Hospital de Santa Maria, Lisbon, Portugal, ²⁹Great Ormond Street Hospital, London, United Kingdom, ³⁰Tel Aviv University, Tel Aviv, Israel, ³¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ³²Charite, Berlin, Germany, ³³KC Niš, Niš, Serbia, ³⁴German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ³⁵Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhavn, Denmark, ³⁶Stony Brook Children's Hospital, Stony Brook, NY, ³⁷University of Missouri, Columbia, ³⁸Meir Medical Center, Kfar Saba, Israel
Background/Purpose: Juvenile systemic sclerosis(jSSc) is an orphan disease with a prevalence in around 3 in a million children[1]. Pulmonary involvement in jSSc occurs in approximately 40…
Abstract Number: 1831 • 2019 ACR/ARP Annual Meeting
Subtypes of Scleroderma Lung Involvement Associated with Burden of Disease and Outcomes
Sarah French¹, Kim Taylor ¹, Stephanie Rush ² and Francesco Boin ¹, ¹UCSF, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA
Background/Purpose: Pulmonary disease is a leading cause of mortality in scleroderma (SSc). Previous studies indicate that the coexistence of pulmonary hypertension (PH) and interstitial lung…
Abstract Number: 2603 • 2019 ACR/ARP Annual Meeting
Course of Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in the EUSTAR Database
Anna-Maria Hoffmann-Vold¹, Yannick Allanore ², Margarida Alves ³, Nicole Graf ⁴, Paolo Airò ⁵, Lidia P. Ananyeva ⁶, László Czirják ⁷, Serena Guiducci ⁸, Eric Hachulla ⁹, Mengtao Li ¹⁰, Carina Mihai ¹¹, Gabriela Riemekasten ¹², Petros Sfikakis ¹³, Gabriele Valentini ¹⁴, Otylia Kowal-Bielecka ¹⁵ and Oliver Distler ¹⁶, ¹Dept. of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ²Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ³Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁴Graf Biostatistics, Winterthur, Switzerland, Winterthur, Switzerland, ⁵UO Reumatologia e Immunologia Clinica, Spedali Civili di Brescia, Brescia, Italy, Brescia, Italy, ⁶VA Nasonova Institute of Rheumatology, Moscow, Russian Federation, Moscow, Russia, ⁷Dept. of Rheumatology and Immunology, University of Pécs, Pécs, Hungary, Pécs, Hungary, ⁸Dept. of Clinical and Experimental Medicine, Section of Rheumatology, University of Florence, Italy, Florence, Italy, ⁹Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, ¹⁰Dept. of Rheumatology, Peking Union Medical College Hospital (West Campus), Beijing, China, Beijing, China (People's Republic), ¹¹Dept. of Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, ¹²Dept. of Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein, Lübeck, Germany, Lübeck, Germany, ¹³Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹⁴Dipartimento di Medicina di Precisione, II Policlinico U.O. Reumatologia, Napoli, Italy, Napoli, Italy, ¹⁵Dept. of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, Bialystok, Poland, ¹⁶Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: The course of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is heterogeneous; some patients may experience rapid decline in lung function, while others have relatively…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].